NCT06075771View on ClinicalTrials.gov

Dopaminergic Therapy for Anhedonia - 2

PHASE4RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
AnhedoniaDepression
Interventions
DRUG

Carbidopa Levodopa

Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.

DRUG

Placebo

A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.

Trial Locations (1)

30322

RECRUITING

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER